4. INTRDOUCTION Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries. In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse
5. Mission & Vision To become a research based International pharmaceutical company. VISSION-2012 Achieve significant business with a strong presence in developed market.
10. Financials Ranbaxy was incorporated in 1961 and went public in 1973. For the year 2009, the Company recorded Global Sales of US $ 1519 Mn. The Company has a balanced mix of revenues from emerging and developed markets that contribute 54% and 39% respectively. In 2009, North America, the Company's largest market contributed sales of US $ 397 Mn, followed by Europe garnering US $ 269 Mn and Asia clocking sales of around US $ 441
11. Strategy Ranbaxy is focused on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes. Growth is well spread across geographies with focus on emerging markets. The Company continues to evaluate acquisition opportunities in India, emerging and developed markets to strengthen its business and competitiveness. Ranbaxy has forayed into high growth potential segments like Biologics, Oncology and Injectables. These new growth areas will add significant depth to the existing product pipeline.
12. Current market share Market Share of Ranbaxy The Company is currently ranked 2nd in the Indian pharmaceutical market with 4.98% market share (IMS, Oct-Dec’09). Global sales in 2009 were USD 1,519 Mn (Rs. 73,441 Mn), De-growth of 9% over previous year. In Rupee terms, sales grew moderately by 1%. Sales during the Quarter recorded growth of 25% at USD 482 Mn (Rs. 22,699 Mn). Emerging markets accounted for 54% of sales during the year, while developed markets contributed
13. Ranbaxy Top products Simvastain Control hypercholesterolemia and to prevent cardiovascular disease. AmoxiClav potassium Used to treat a broad –spectrum of bacterial infections. Isotretinoin. for the treatment of brain cancer. Ciprofloxacin. It kills bacteria by interfering. Omeprazole Used in the treatment of dyspepsia
14. MAJOR COMPETITOR COMPANIESTOTAL ASSETS ( Cr. ) SUN PHARMA 5.747.47 DR Reedy labs 6,477,80 CIPLA 5,919,16 RANBAXY 7,482,99 LUPIN 3,437,36 GlaxoSmithKline 1,764,57 Cadillac Health 2,216,20 Primal Health 2,527,81 Glen mark 2,527,93
17. Major Achievements of Ranbaxy India's largest pharmaceutical company. Received The Economic Times Award for Corporate Excellence for 'The Company of the Year 2002-2003'. Ranbaxy is among the elite club of Million Dollar Companies. Ranbaxy received India's first approval from USFDA for an Anti Retroviral (ARV) drug under the U.S. President's Emergency Plan for AIDS Relief.
